Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSL689
- Development stage
- Phase 1
- Lead developer
- CSL Behring
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
CSL689 is a recombinant fusion protein that links activated human coagulation factor VIIa (FVIIa) with human albumin (rVIIa-FP). This design extends the half-life of FVIIa in circulation. CSL689 acts as a tissue factor inhibitor and is intended for intravenous infusion to treat bleeding episodes, particularly in patients with hemophilia A or congenital factor VII deficiency. The drug was developed by CSL Behring and has reached Phase 3 clinical trials for indications including hemorrhage and hemophilia A[1][2][3][4][7].
- Other names
- recombinant fusion protein linking human coagulation factor viia with human albumin
02
Targets
F3 (Tissue factor)
Beyond the preview
Go deeper on CSL689.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSL689.